Key result
Pre-TMVr heart failure duration >18 months linked to ~112% higher 1-year mortality or rehospitalization risk.
Why the study?
Little was known about the association between heart failure chronicity and clinical outcomes after transcatheter mitral valve repair for functional mitral regurgitation.
Is longer heart failure duration (>18 months) associated with increased mortality or heart failure rehospitalization in patients undergoing transcatheter mitral valve repair for functional mitral regurgitation?
Cohort (n=208)
Is longer heart failure duration (>18 months) associated with increased mortality or heart failure rehospitalization in patients undergoing transcatheter mitral valve repair for functional mitral regurgitation?
A longer duration of heart failure prior to transcatheter mitral valve repair for functional mitral regurgitation is associated with worse 1-year clinical outcomes, suggesting the importance of timely intervention.
Answers are grounded in this paper and cite their sources.
Longer HF duration before TMVr was associated with worse 1-year outcomes; hypothesis-generating for earlier intervention in functional MR.
BACKGROUND: Little is known about the association of heart failure (HF) chronicity with clinical outcomes after transcatheter mitral valve repair (TMVR) for functional mitral regurgitation (MR). METHODS: From January 2011 to March 2019, consecutive patients with functional MR who underwent a MitraClip procedure were analyzed. The patients were divided into two groups according to HF duration-those with duration ≤18 months and those with >18 months. The primary outcome measure was a composite of all-cause mortality and re-HF rehospitalization within 1 year after the procedure. These outcomes were also assessed separately. A Cox proportional hazard model was conducted for investigating the association of HF duration with the primary outcome. RESULTS: A total of 208 patients were analyzed. Patients with HF duration >18 months had a higher rate of the primary outcome compared to those with HF duration ≤18 months (38.1 vs. 19.0%, log-rank p = .003). A longer duration of HF was associated with an increased risk of the primary outcomes (adjusted-HR of >18 months, 2.12 95% CI, 1.14-4.19; p = .03; adjusted-HR (hazard ratios) for 1 year increase, 1.05; 95% CI, 1.02-1.09; p = .004). The association of HF duration with the primary outcomes showed a steep rise during the first 2 years of HF duration and progressive increase after 5 years. CONCLUSIONS: A longer HF duration before TMVR was associated with an increased risk of all-cause mortality or HF rehospitalization. HF duration can be used for the risk stratification marker in patients undergoing TMVR for functional MR.
No takes yet. Share an insight, caveat, or question.
Sugiura et al. (2020) conducted a cohort in Functional mitral regurgitation (n=208). Heart failure duration >18 months vs. Heart failure duration ≤18 months was evaluated on Composite of all-cause mortality and heart failure rehospitalization within 1 year after the procedure (adjusted-HR 2.12, 95% CI 1.14-4.19, p=0.03). Heart failure duration >18 months before transcatheter mitral valve repair increased the risk of 1-year mortality or heart failure rehospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: